ContraFect Corp has a consensus price target of $3 based on the ratings of 4 analysts. The high is $7 issued by WBB Securities on June 8, 2022. The low is $1 issued by SVB Leerink on July 14, 2022. The 3 most-recent analyst ratings were released by Maxim Group, SVB Leerink, and Cantor Fitzgerald on April 13, 2023, July 14, 2022, and July 14, 2022, respectively. With an average price target of $1.67 between Maxim Group, SVB Leerink, and Cantor Fitzgerald, there's an implied 3233.33% upside for ContraFect Corp from these most-recent analyst ratings.
1calculated from analyst ratings
The latest price target for ContraFect Corp (OTC:CFRX) was reported by Maxim Group on April 13, 2023. The analyst firm set a price target for $3.00 expecting CFRX to rise to within 12 months (a possible 5900.00% upside). 0 analyst firms have reported ratings in the last year.
The latest analyst rating for ContraFect Corp (OTC:CFRX) was provided by Maxim Group, and ContraFect Corp upgraded their buy rating.
The last upgrade for ContraFect Corp happened on April 13, 2023 when Maxim Group raised their price target to $3. Maxim Group previously had a hold for ContraFect Corp.
The last downgrade for ContraFect Corp happened on July 14, 2022 when Maxim Group changed their price target from N/A to N/A for ContraFect Corp.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ContraFect Corp, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ContraFect Corp was filed on April 13, 2023 so you should expect the next rating to be made available sometime around April 13, 2024.
While ratings are subjective and will change, the latest ContraFect Corp (CFRX) rating was a upgraded with a price target of $0.00 to $3.00. The current price ContraFect Corp (CFRX) is trading at is $0.05, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.